Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
18.5M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
8.05M
-
Shares change
-
+938K
-
Total reported value, excl. options
-
$13.3M
-
Value change
-
+$1.5M
-
Number of buys
-
22
-
Number of sells
-
-19
-
Price
-
$1.65
Significant Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q2 2025
51 filings reported holding VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.05M shares
of 18.5M outstanding shares and own 43.47% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (1.37M shares), CITADEL ADVISORS LLC (1.04M shares), ACORN CAPITAL ADVISORS, LLC (737K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (644K shares), DAFNA Capital Management LLC (636K shares), KENNEDY CAPITAL MANAGEMENT LLC (571K shares), VANGUARD GROUP INC (496K shares), Palo Alto Investors LP (445K shares), Patient Square Capital LP (317K shares), and Ikarian Capital, LLC (290K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.